Other study done by Jeong et al., 2011 who showed that AML patients who responded to treatment had decreasing SALL4 expression throughout the course of treatment, while AML patients with disease relapse or drug resistance had increasing SALL4 expression, which was correlated with disease progression. This evidence concerns the gene SALL4 and acute myeloid leukemia.